Nicholas Bracciano
Psychiatry · Milwaukee, WINPI 1497140453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $571 and has fallen 51.0% since, to $280 in 2025.
Across 124 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$420
- Alkermes, Inc.$417
- Lundbeck LLC$318
- Otsuka America Pharmaceutical, Inc.$162
- Indivior Inc.$150
- Orexo US, Inc.$140
- plus $763 from 16 others
What the payments were for
- Food & beverage$2,370100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $420 |
| Alkermes, Inc. | 18 | $417 |
| Lundbeck LLC | 16 | $318 |
| Otsuka America Pharmaceutical, Inc. | 8 | $162 |
| Indivior Inc. | 7 | $150 |
| Orexo US, Inc. | 9 | $140 |
| Bausch Health US, LLC | 6 | $119 |
| Neurocrine Biosciences, Inc. | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $83 |
| Johnson & Johnson | 4 | $80 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $57 |
| Eisai Inc. | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| USWM, LLC | 3 | $39 |
| Corium, LLC | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Tris Pharma Inc | 2 | $35 |
| Sage Therapeutics, LLC | 1 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Braeburn Inc. | 1 | $14 |
How this compares
$2,370 in reported general payments places this provider in the 85th percentile of 543 psychiatry providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 31 | $498 |
| Divalproex Sodium | 22 | $304 |
| Haloperidol | 18 | $286 |
| Hydroxyzine Hcl | 11 | $258 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Milwaukee
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Jacob BehrensMilwaukee$94K
- Selahattin KurterMilwaukee$17K
- Harold HarschMilwaukee$8K
- Ajay SehgalMilwaukee$7K
- James WinstonMilwaukee$7K
- Edgar JacksonMilwaukee$5K
- Ali ArtarMilwaukee$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.